Start-Up Spotlight: Bio2 Technologies Inc., Space-Tech Biomaterial For Extremities Surgery

 
• By Bob Kronemyer

Originating from aerospace technology, Bio2 Technologies’ Vitrium biomaterial platform is designed for multiple applications across musculoskeletal surgery. The firm has already begun commercialization in the US and expects to get a CE mark later this year.

Light bulbs in a row with one being on, large group of people with a few moving to the light.Leading the pack, ingenuity,taking the initiative,standing out from the crowd concept.
Medtech Insight's Start-Up Spotlight • Source: shutterstock.com

A resorbable, inorganic material that has the ability to elicit bone remodeling comparable to biologic materials looks promising for orthopedic extremity surgery. Because it is synthetic, Vitrium from Bio2 Technologies Inc. does not carry the risk of biologic materials, and is much less expensive, according to president and CEO Paul Nichols.

Vitrium is a three-dimensional porous scaffold that can also withstand physiologic loads. “The product has broad application across musculoskeletal medicine,”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Orthopedics

More from Device Area

SS Innovations’ SSI Mantra 3 Poised To Challenge Da Vinci In Robotic Surgery Market

 
• By Marion Webb

SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

Philips Deals Itself A Strong Hand In POCUS Stakes

 
• By Ashley Yeo

Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.